Final piece of growth hormone to which its fat-burning effect is attributed. It is practically the same compound as AOD-9604 (which has an added tyrosine) and has no approval or published trials showing benefit in people.
Regulatory status
Not approved
Family
Fragment of human growth hormone (C-terminal end)
Scientific evidence
Low
Number of findings
2
Where it acts
Digestive and weight · Hormones and metabolism
Also known as
HGH Fragment 176-191, hGH 176-191, Frag 176-191
Regulatory status
FDA (US): Not approved
EMA (EU): Not approved
Dose
There is no established dose in humans.
Safety
No published human safety data for the product sold under this name. Reviews on GH-axis peptides describe glucose disturbances, fluid retention, and injection-site reactions with unregulated products of uncertain composition. Its use only makes sense in research or under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Weight in obese rats (AOD-9604 analog)
reducesLowpreclinical (A)animals / laboratory
With the AOD-9604 analog, obese rats gained less than half the weight of untreated ones in 19 days.
A 2026 review of GH-IGF-1 axis peptides concludes that the benefits on body composition are very uncertain and that the composition of products on the market is doubtful.
Mimics the region of growth hormone that stimulates lipolysis in adipose tissue, without binding to the hormone receptor in the same way. For this reason, in theory, it does not raise IGF-1 or glucose.
What the evidence says
In people
Benefits in humans very uncertain. A 2026 review of GH-IGF-1 axis peptides concludes that the benefits for body composition are very uncertain and that the composition of products on the market is doubtful. PubMed 42395176
In animals or the laboratory
Weight in obese rats (AOD-9604 analog). With the AOD-9604 analog, obese rats gained less than half the weight of untreated rats in 19 days. PubMed 11146367